Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium.
AIDS. 2011 Jun 19;25(10):1332-3. doi: 10.1097/QAD.0b013e328347c083.
Immune activation and chronic inflammation are recognized as major component of HIV disease even in patients with undetectable viral load. We evaluated the effect of atorvastatin on CD38 activation in such patients, in a case-control study (133 cases - 266 controls). At week 48, CD38 activation was significantly lower in cases vs. controls, with no difference in high-sensitivity C-reactive protein (hsCRP) and CD4. These results suggest that atorvastatin reduces the level of immune activation in patients with undetectable viral load.
免疫激活和慢性炎症被认为是 HIV 疾病的主要组成部分，即使在病毒载量不可检测的患者中也是如此。我们在一项病例对照研究（133 例病例-266 例对照）中评估了阿托伐他汀对这些患者 CD38 活化的影响。在第 48 周时，病例组的 CD38 活化明显低于对照组，而高敏 C 反应蛋白（hsCRP）和 CD4 无差异。这些结果表明阿托伐他汀可降低病毒载量不可检测患者的免疫激活水平。
